Premium
Langerhans‐cell histiocytosis—excellent response to etoposide
Author(s) -
MAYOU S.C.,
CHU A.C.,
MUNRO D.D.,
PLOWMAN N.
Publication year - 1991
Publication title -
clinical and experimental dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.587
H-Index - 78
eISSN - 1365-2230
pISSN - 0307-6938
DOI - 10.1111/j.1365-2230.1991.tb00379.x
Subject(s) - langerhans cell histiocytosis , etoposide , medicine , histiocytosis , dermatology , immunology , pathology , chemotherapy , disease
Summary We describe an adult with progressive LCH who received oral etoposide as primary treatment. The response is documented and the strategical implications of this drug in Langerhans‐cell histiocytosis discussed. Langerhans‐cell histiocytosis (LCH) is the term recognized since 1987 for the group of diseases previously designated histiocytosis X, 1 It is not now regarded as a malignant neoplastic process and there is some evidence to suggest that it is due to abnormal immunity, 2 but cytotoxic drugs and steroids are still the mainstay of systemic treatment. Etoposide (VP16) is a semisynthetic epipodophyllotoxin derivative effective in the treatment of malignancies of the mono‐cyte‐macrophage lineage and used in resistant or relapsed childhood LCH. 3,4 There are no previous reports of its use as firstline monotherapy in adults with LCH.